Dimensional Fund Advisors LP raised its holdings in shares of Intra-Cellular Therapies Inc (NASDAQ:ITCI) by 1.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,444,223 shares of the biopharmaceutical company’s stock after buying an additional 24,335 shares during the period. Dimensional Fund Advisors LP owned about 2.64% of Intra-Cellular Therapies worth $16,450,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of ITCI. GSA Capital Partners LLP purchased a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth about $142,000. Creative Planning purchased a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth about $228,000. Citigroup Inc. boosted its holdings in shares of Intra-Cellular Therapies by 19.7% during the fourth quarter. Citigroup Inc. now owns 22,585 shares of the biopharmaceutical company’s stock worth $257,000 after purchasing an additional 3,719 shares during the period. First Trust Advisors LP purchased a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth about $274,000. Finally, MetLife Investment Advisors LLC boosted its holdings in shares of Intra-Cellular Therapies by 55.8% during the third quarter. MetLife Investment Advisors LLC now owns 30,540 shares of the biopharmaceutical company’s stock worth $663,000 after purchasing an additional 10,934 shares during the period. Institutional investors and hedge funds own 68.88% of the company’s stock.
A number of analysts have recently weighed in on ITCI shares. ValuEngine lowered shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a report on Thursday, January 24th. Zacks Investment Research downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research note on Thursday, December 20th. BidaskClub downgraded shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $26.00 price target on shares of Intra-Cellular Therapies in a research note on Monday. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $27.00.
ITCI stock opened at $12.67 on Wednesday. Intra-Cellular Therapies Inc has a 1 year low of $10.21 and a 1 year high of $23.64. The stock has a market capitalization of $696.72 million, a P/E ratio of -4.46 and a beta of 1.39.
Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Wednesday, February 27th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.91) by $0.16. On average, analysts anticipate that Intra-Cellular Therapies Inc will post -4.05 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Dimensional Fund Advisors LP Has $16.45 Million Holdings in Intra-Cellular Therapies Inc (ITCI)” was first published by Macon Daily and is the sole property of of Macon Daily. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://macondaily.com/2019/04/17/dimensional-fund-advisors-lp-has-16-45-million-holdings-in-intra-cellular-therapies-inc-itci.html.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.
Read More: What is a put option?
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.